Skip to main content
MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM
September 1, 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
August 31, 2021
Participation terms in the MedinCell Combined General Meeting
August 4, 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report
July 28, 2021
MedinCell announces the initiation of coverage of its stock by ODDO-BHF
July 26, 2021
MedinCell announces fiscal year consolidated results April 2020 – March 2021
June 16, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
June 14, 2021
Videoconference and publication of the results for the 2020-2021 financial year, on June 16, 2021
June 1, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
April 19, 2021
Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis
March 5, 2021
